GLOBAL nanotechnology company pSivida Limited’s UK operating subsidiary pSiMedica has been granted a further patent in the US market.
The patent provides for a method of implanting an electronic device within a living animal or human body, wherein the device includes bioactive silicon and a method of delivering a drug to a living animal or human by placing the drug to be delivered on or within a bioactive silicon structure.
pSivida managing director Gavin Rezos said the new US patent was an important addition to the company’s intellectual property portfolio.
"The patent will draw further attention in the US to the versatility of the BioSilicon technology platform and, in particular, to large value-adding electronics and chip companies looking to develop ‘smart’ devices with potential applications in controlled drug delivery and diagnostics.
© Business News 2018. You may share content using the tools provided but do not copy and redistribute.